UCSF

Akinyemi Oni-Orisan, PharmD, PhD

Assistant Professor
Department of Clinical Pharmacy
Oni-Orisan
Credit: 
Myra Gloria
[email protected]
Phone: +1 415 502-7551
Fax: +1 415 476-1356
513 Parnassus Avenue, Rm 966B
UCSF Box 0794
San Francisco, CA 94143
United States

Links

UCSF Profiles

What I do

I conduct translational research investigating therapies for cardiovascular disease using precision medicine approaches.

Departmental research area

Clinical research

My research expertise

Pharmacogenomics, Pharmacoepidemiology, Pharmacometrics, electronic health records, pharmacometabolomics

Clinical expertise

Cardiovascular disease risk reduction; Lipid management

Degrees

PhD, Pharmacotherapy and Experimental Therapeutics, University of North Carolina
PharmD, University of Michigan
BS, Biology, University of Michigan

Research keywords

Eicosanoids, Epoxide Hydrolases, Arachidonic Acids, Arachidonic Acid, Cytochrome P-450 Enzyme System

Publications

Oni-Orisan A, Hoffmann TJ, Ranatunga D, Medina MW, Jorgenson E, Schaefer C, Krauss RM, Iribarren C, Risch N. Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort. Circ Genom Precis Med. 2018 Sep; 11(9):e002043.
Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, Lee CR. Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome. Prostaglandins Other Lipid Mediat. 2018 Sep; 138:15-22.
Dong OM, Li A, Suzuki O, Oni-Orisan A, Gonzalez R, Stouffer GA, Lee CR, Wiltshire T. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. Pharmacogenomics. 2018 Jun 01; 19(9):771-782.
Bai X, Mangum KD, Dee RA, Stouffer GA, Lee CR, Oni-Orisan A, Patterson C, Schisler JC, Viera AJ, Taylor JM, Mack CP. Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. J Clin Invest. 2017 Feb 01; 127(2):670-680.
Oni-Orisan A, Edin ML, Lee JA, Wells MA, Christensen ES, Vendrov KC, Lih FB, Tomer KB, Bai X, Taylor JM, Stouffer GA, Zeldin DC, Lee CR. Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. J Lipid Res. 2016 Jan; 57(1):109-19.
Oni-Orisan A, Lanfear DE. Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev. 2014 Sep-Oct; 22(5):193-8.
Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM. Epoxyeicosatrienoic acids and cardioprotection: the road to translation. J Mol Cell Cardiol. 2014 Sep; 74:199-208.
Cicci JD, Reed BN, McNeely EB, Oni-Orisan A, Patterson JH, Rodgers JE. Acute decompensated heart failure: evolving literature and implications for future practice. Pharmacotherapy. 2014; 34(4):373-88.
Oni-Orisan A, Deng Y, Schuck RN, Theken KN, Edin ML, Lih FB, Molnar K, DeGraff L, Tomer KB, Zeldin DC, Lee CR. Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:67-73.
Theken KN, Deng Y, Schuck RN, Oni-Orisan A, Miller TM, Kannon MA, Poloyac SM, Lee CR. Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am J Physiol Endocrinol Metab. 2012 Mar 01; 302(5):E500-9.
Make a gift
We see a time when precise therapeutics—used safely and effectively—improve the health of people everywhere.
© 2002–2019 The Regents of the University of California